
    
      This is a Phase II/III, randomized, two-part, multi-center study, in which subjects with
      advanced or metastatic neuroendocrine carcinoma will be enrolled.

      This study will be conducted in two parts:

      Part 1, the Phase II study was to: (i) evaluate the safety and tolerability of the FOLFSIM
      regimen plus Toripalimab; and (ii) identify the recommended dose; (iii) assess the antitumor
      activity; (iv) the pharmacokinetic (PK) parameters of the drugs in the regimen.

      Part 2, the Phase III study was to verify inferiority of FOLFSIM regimen plus Toripalimab
      compared with the current standard chemotherapy (EP/EC regimen) in the first-line treatment
      of advanced or metastatic neuroendocrine carcinoma.
    
  